Once you accept that mitochondrial decline is one of the central nodes of aging — not a side effect but a driver — the natural next question is the practical one: how are researchers trying to address it? The research answering that question is sprawling, but it organizes surprisingly cleanly. Many of the most prominent approaches fall into one of three strategies, each aimed at a different way mitochondria fail. Seeing all three at once is the clearest possible map of where mitochondrial medicine stands, and it is a genuinely exciting view.
Path one: protect the structure
The first strategy treats the mitochondrion as a physical object that wears out, and tries to keep it intact. The inner membrane’s folded architecture — held together in part by the lipid cardiolipin — is where energy production physically happens, and it degrades under oxidative stress and age. Protect that architecture, the logic goes, and efficiency holds.
This is the domain of SS-31 (elamipretide), the cardiolipin-binding peptide that in 2025 became the first mitochondria-targeted therapeutic the FDA ever approved, for the rare cardiolipin disorder Barth syndrome. It is the path with the most concrete clinical proof-of-concept to date — a real human approval — tempered by the honest caveat that the win is in one mechanism-matched rare disease, not yet in general aging. The structural path has shown, at least once, that the mitochondrion itself can be a winning drug target.
Path two: restore the metabolic inputs
The second strategy is metabolic. Mitochondria depend on cofactors, and the most discussed of these is NAD+, the redox coenzyme that carries the electrons energy production depends on and supplies the enzymes that repair and regulate the cell. NAD+ appears to fall with age, so the idea is to replenish it — usually with precursors like NR and NMN that the body converts into NAD+.
This is the story told in NAD+ and the aging cell, and it is instructive precisely because the two halves of it sit at different stages. Engaging the NAD+ pathway in people is achievable — the precursors reach their target and look safe. Translating that into measurably better strength or healthspan is not yet established; human trials have so far shown limited clinical benefit despite powerful animal data, as a 2025 Nature Metabolism review lays out. The metabolic path has the deepest mechanistic reach and the clearest example of the difference between engaging a target and improving an outcome.
Path three: strengthen the signals
The third strategy is neither structural nor purely metabolic — it works through communication. Mitochondria are signaling organelles, and some of the most intriguing molecules in the field are the messages they send. MOTS-c, a peptide encoded inside the mitochondrial genome, rises with exercise, declines with age, and acts through the cell’s energy sensor AMPK to switch on adaptive, stress-resisting programs. In animal studies, supplementing it improved insulin sensitivity, protected against diet-induced weight gain, and enhanced physical performance in young, middle-aged, and older mice.
This path is the least clinically mature of the three — MOTS-c’s compelling results are still largely preclinical, with the decisive human trials ahead — but conceptually it may be the richest, because it targets not a part but a program: the cell’s own capacity to adapt. Strengthening the signals means helping mitochondria respond better to stress, rather than only repairing or refueling them.
The path that cuts across all three
There is a fourth thing worth naming, because it has the broadest evidence base for supporting mitochondrial health: exercise. It is the most robustly evidenced mitochondrial intervention in existence, and it is striking that it influences all three layers at once — it builds new mitochondria and improves their quality (structure), reshapes the cell’s metabolic and NAD+ economy (metabolic), and is itself the natural trigger for adaptive signals like MOTS-c (signaling). The engineered strategies are, in a real sense, attempts to capture pharmacologically what movement already does biologically. That is not a knock on the science — it is a clue about what “working” looks like, and a reminder of the benchmark any intervention is measured against.
Reading the map honestly
Laid out together, the three paths make the state of play legible. The structural path has a genuine clinical foothold in a rare disease and open questions everywhere else. The metabolic path has unmatched mechanistic depth and a still-unproven bridge to human benefit. The signaling path has the most conceptual promise and the least human data. None of these is the answer; each is a distinct, active line of inquiry, and the eventual toolkit will likely draw on all of them.
That plurality is the point, and the reason to be optimistic without overclaiming. Mitochondrial resilience is unlikely to come from a single molecule alone, but rather from understanding a multi-layered system well enough to support it at several levels at once. Watching all three paths advance — at their different speeds, with their different kinds of evidence — is one of the most rewarding ways to follow longevity science as it is actually being written.